Prostate Cancer

Apalutimide in combination with androgen deprivation therapy led to a significant improvement in overall survival in patients with nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN clinical trial.

"The CONDOR study met its primary endpoint. Indeed, it well exceeded it. And it demonstrated excellent diagnostic performance of PyL PET in men with biochemically relapsed prostate cancer, even at very low PSA values."

"Relugolix is a novel, oral GnRH antagonist that has the potential to become a new standard for ADT in advanced prostate cancer."

“Lu-PSMA is a novel class of therapy with high activity and relatively low toxicity, consistent with the results of prior single-center studies in phase II data. Lu-PSMA appears to represent a favorable treatment option compared to cabazitaxel in a selected population with high PSMA-expression.”

Aaron E. Katz, MD, discusses a genomic test for patients with low-risk prostate cancer.

In an interview with Targeted Oncology, following a tweet chat on prostate cancer, Tian Zhang, MD, discussed the key takeaways from the tweet chat discussion and highlighted both the role of molecular testing and the impact of the recent FDA approvals in prostate cancer.

Two companion diagnostic assays were granted FDA approval to identify male patients with metastatic castration-resistant prostate cancer who are eligible for treatment with olaparib.

The FDA has approved olaparib for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious germline or somatic HRR gene mutations and have progressed following prior treatment with a new hormonal agent.

“Although PARP inhibitor treatment has demonstrated radiographic and PSA responses in patients with BRCA alterations (4–8), the data presented here offer compelling evidence that response to PARP inhibitors is limited in men with mCRPC harboring an ATM, CDK1/2, or CHEK2 alteration."

Cabazitaxel demonstrated better patients-reported outcomes compared with either abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer.

Positive safety and efficacy outcomes were witnessed in the KEYNOTE-365 study , supporting further assessment of the combination of pembrolizumab and enzalutamide in a larger population of patients with metastatic castration resistance prostate cancer.

"Rucaparib’s approval could have a profound impact on patients with BRCA2 and BRCA1 mutations, who have no other targeted treatment option available to them based on this mutation."

"Historically, neoadjuvant hormone therapy has been shown to improve pathologic outcomes. Therefore, neoadjuvant androgen deprivation therapy may allow a nerve-sparing surgical approach to increase post-surgical quality-of-life outcomes without compromising oncologic outcomes.”

A significant improvement in overall survival was observed with darolutamide plus androgen deprivation therapy compared with androgen deprivation therapy alone in men with non-metastatic castration-resistant prostate cancer treated in the phase III ARAMIS trial.

Scott T. Tagawa, MD, MS, discusses a phase I dose-escalation study of actinium-225 in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor.

Daniel J. George, MD, discusses how cabazitaxel can impact the sequencing approaches physicians use to treat patients with metastatic castration-resistant prostate cancer.

Results from the phase Ib/II study of VERU-111 in patients with metastatic castration-resistant prostate cancer have prompted plans to meet with the FDA in the third quarter of 2020 to discuss the trial design for a phase III clinical trial of VERU-111 for this indication.

"We made the decision to prioritize this NDA submission and potentially accelerate the availability of an oral treatment option for men with advanced prostate cancer...”

Pembrolizumab plus enzalutamide in castration- resistant prostate cancer that exhibited enzalutamide resistance led to positive antitumor signals and a favorable safety profile, according to results of the phase II KEYNOTE-199  trial presented  at the 2020  Genitourinary Cancers Symposium.

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Stephen J. Freedland, MD, discusses real-world data for enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.

External Beam Radiation therapy with or without androgen deprivation therapy or surgery are the standards of care for men with intermediate-risk prostate cancer, but the adverse events associated with the treatments, delayed testosterone recovery and prolonged erectile dysfunction, are challenges.

An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.

A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.

At the Annual Education Summit of the Medical Oncology Association of Southern California, Tanya Dorff, MD, discussed evolving practices in prostate and urothelial cancers as well as highlighted controversies in the treatment landscape such as the role of combination therapy in prostate cancer.